Looking to focus its efforts in proprietary drug discovery and development platforms, Otsuka Pharmaceutical has acquired the biotech firm, Visterra, to venture into the antibody space for an all-cash transaction of US$430 M. The deal is expected to close in the third quarter. This is the second acquisition by Otsuka in the space of a week - the first was the acquisition of ReCor Medical, giving Otsuka access to the renal denervation market for an undisclosed sum.